Arcus Biosciences Inc. (RCUS)
RCUS trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/0001724521-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RCUS on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001724521 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $247.0M |
| Net income | -$353.0M |
| Operating income | -$386.0M |
| Net margin | -142.9% |
| Operating margin | -156.3% |
| Revenue growth | -4.3% |
| Cash | $222.0M |
| Total assets | $1.1B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 9.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $151.0M cash; operating cash flow -$116.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 143,990,614 (2026-10-29); 107,973,536 a year earlier; 74,855,565 three years earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns | Latest 2026-10-22 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2026-03-11 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $13.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $9.0M | -$128.0M | -$88.0M | $151.0M | $102.0M | $100.0M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $41.0M | -$91.0M | -$119.0M | $150.0M | $101.0M | $117.0M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $17.0M | -$128.0M | -$138.0M | $201.0M | $100.0M | $236.0M | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $33.0M | -$106.0M | -$120.0M | $222.0M | $99.0M | $247.0M | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | $26.0M | -$135.0M | -$97.0M | $238.0M | $98.0M | $240.0M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $160.0M | $0 | -$133.0M | $248.0M | $97.0M | $262.0M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $28.0M | -$112.0M | -$132.0M | $192.0M | $48.0M | $141.0M | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $26.0M | -$94.0M | -$100.0M | $150.0M | $48.0M | $258.0M | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-10-22 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 609 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.6% |
| 1 month | -22.6% |
| 3 months | -39.6% |
| Year to date | -26.9% |
| 1 year | -11.9% |
| From 52-week high | -44.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Company N.V. | $19.46 | -3.38% | $2.3B |
| HCM | HUTCHMED (China) Limited | $14.73 | -1.14% | $2.6B |
| LKFT | Lakefront Biotherapeutics | $34.79 | +2.38% | $2.3B |
| PBH | Prestige Consumer Healthcare Inc. | $48.00 | +3.92% | $2.3B |
| PHVS | Pharvaris N.V. | $32.44 | -2.76% | $2.3B |
| PRGO | Perrigo Company plc | $16.18 | -0.37% | $2.2B |
| MBX | MBX Biosciences Inc. | $53.12 | -5.04% | $2.6B |
| ZLAB | Zai Lab Limited | $23.47 | -4.59% | $2.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier